Opportunity Information: Apply for PAR 16 094
Apply for PAR 16 094
- The HHS-NIH11 in the environment, health sector is offering a public funding opportunity titled "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113, 93.121, 93.351, 93.855, 93.856.
- This funding opportunity was created on Feb 09, 2016 and posted on Feb 09, 2016.
- Applicants must submit their applications by May 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R21)" (Funding Opportunity Number PAR 16-094) is a discretionary NIH program that supports exploratory and developmental research aimed at making animal models more useful and predictive for stem cell-based regenerative medicine. It is built around the idea that progress toward safe and effective stem cell therapies depends heavily on having animal systems that accurately reflect human biology and human disease, particularly when researchers are trying to understand how transplanted stem cells behave, integrate, and affect tissues over time.
At its core, this funding announcement seeks projects that either improve existing animal models or create new ones specifically tailored to studying human disease conditions in the context of stem cell therapy. A major emphasis is on characterizing animal stem cells and comparing them directly with human stem cells so the field can better judge which species and which model systems are most informative for specific therapeutic questions. That comparative work is intended to help researchers choose models that are more predictive of human outcomes, rather than relying on convenient but potentially misleading systems.
The FOA highlights three main research directions. First, it encourages comparative analysis of animal versus human stem cells, which can include examining similarities and differences in stem cell identity, potency, differentiation capacity, immunologic behavior, and functional performance in relevant tissues. The goal is practical: identify which animal stem cells and animal hosts best represent human stem cell behavior so that preclinical studies produce results that translate more reliably into human clinical settings. Second, it calls for development of new technologies that improve stem cell characterization and transplantation. This can cover methods that better track transplanted cells, assess their fate and function, measure safety signals like aberrant growth, and improve delivery or engraftment in target tissues. Third, it supports improving animal disease models for stem cell-based therapeutic applications, meaning models that more faithfully reproduce disease mechanisms, tissue environments, and clinically relevant endpoints so that stem cell interventions can be tested under conditions that resemble the real therapeutic challenge.
The mechanism is an NIH Exploratory/Developmental Research Grant (R21), which is designed for early-stage, high-impact ideas and proof-of-concept work rather than large, mature programs. The listed award ceiling is $200,000, reflecting the smaller, exploratory nature of the mechanism. The opportunity was posted and created on February 9, 2016, and the closing date shown is May 7, 2019.
Eligibility is broad and includes many types of domestic entities: state, county, and city governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (including small businesses); and additional applicants as allowed under NIH policy language referenced in the opportunity. The sponsoring agency is the U.S. Department of Health and Human Services, National Institutes of Health (HHS-NIH), and the activity aligns with health-related research areas reflected in the CFDA numbers 93.113, 93.121, 93.351, 93.855, 93.856.
Overall, this FOA is geared toward closing a key translational gap in regenerative medicine: turning promising stem cell science into therapies that work in humans by strengthening the preclinical foundation through better animal stem cell characterization, better tools for transplantation and monitoring, and animal disease models that more closely match human conditions and therapeutic realities.
FAQs: Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R21) - PAR 16-094
What is the title and funding opportunity number for this grant?
The opportunity is titled "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R21)" and the Funding Opportunity Number is PAR 16-094.
Which federal agency sponsors this funding opportunity?
The sponsoring agency is the U.S. Department of Health and Human Services, National Institutes of Health (HHS-NIH).
What type of NIH grant mechanism is used for this opportunity?
This FOA uses the NIH Exploratory/Developmental Research Grant mechanism (R21).
What is the overall purpose of this FOA?
The FOA supports exploratory and developmental research to make animal models more useful and predictive for stem cell-based regenerative medicine, with the goal of improving how well preclinical results translate to human outcomes.
Why does this FOA focus on animal models in regenerative medicine?
It is based on the idea that progress toward safe and effective stem cell therapies depends heavily on animal systems that accurately reflect human biology and disease, especially for understanding how transplanted stem cells behave, integrate, and affect tissues over time.
What kinds of projects does this FOA aim to support?
Projects that improve existing animal models or create new animal models tailored to studying human disease conditions in the context of stem cell therapy, especially models that better predict human clinical outcomes.
What are the main research directions emphasized in the FOA?
The FOA highlights three main directions: (1) comparative analysis of animal versus human stem cells, (2) development of new technologies to improve stem cell characterization and transplantation, and (3) improvement of animal disease models for stem cell-based therapeutic applications.
What does "comparative analysis of animal versus human stem cells" mean in this FOA?
It includes directly comparing animal stem cells with human stem cells to understand similarities and differences in areas such as stem cell identity, potency, differentiation capacity, immunologic behavior, and functional performance in relevant tissues.
What is the practical goal of comparing animal and human stem cells?
The practical goal is to identify which animal stem cells and animal hosts best represent human stem cell behavior, so that preclinical studies produce findings that translate more reliably into human clinical settings.
What kinds of technology development does the FOA encourage?
The FOA encourages technologies that improve stem cell characterization and transplantation, including methods to track transplanted cells, assess their fate and function, measure safety signals such as aberrant growth, and improve delivery or engraftment in target tissues.
What does the FOA mean by improving animal disease models for stem cell-based therapies?
It refers to developing or refining animal disease models so they more faithfully reproduce disease mechanisms, tissue environments, and clinically relevant endpoints, allowing stem cell interventions to be tested under conditions that resemble real therapeutic challenges.
Is this FOA intended for large, long-term research programs?
No. Because it uses the R21 mechanism, it is designed for early-stage, potentially high-impact ideas and proof-of-concept work rather than large, mature programs.
What is the maximum award amount listed for this opportunity?
The listed award ceiling is $200,000, reflecting the smaller, exploratory nature of the R21 mechanism as described in the opportunity summary.
When was this funding opportunity posted and created?
The opportunity was posted and created on February 9, 2016.
What is the closing date shown for this funding opportunity?
The closing date shown is May 7, 2019.
Who is eligible to apply for this grant?
Eligibility is broad and includes many types of domestic entities, including: state, county, and city governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (including small businesses); and additional applicants as allowed under NIH policy language referenced in the opportunity.
Are academic institutions eligible?
Yes. Public and state-controlled institutions of higher education and private institutions of higher education are listed as eligible applicants.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education) are listed as eligible.
Are for-profit organizations or small businesses eligible?
Yes. For-profit organizations, including small businesses, are listed among eligible applicants.
Are tribal governments or tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other tribal organizations are included in the eligibility list.
Which broad research area does this FOA align with?
It aligns with health-related research areas within NIH, as reflected by the CFDA numbers listed in the opportunity: 93.113, 93.121, 93.351, 93.855, 93.856.
What translational problem is this FOA trying to address?
It is geared toward closing a key translational gap in regenerative medicine: turning promising stem cell science into therapies that work in humans by strengthening the preclinical foundation through improved animal stem cell characterization, better transplantation and monitoring tools, and animal disease models that more closely match human conditions.
What kinds of outcomes is this FOA trying to improve in preclinical research?
It seeks to improve how accurately preclinical studies predict human outcomes, particularly regarding transplanted stem cell behavior, integration, long-term tissue effects, and safety-related signals.
Does this FOA emphasize choosing "more predictive" model systems over "convenient" ones?
Yes. A stated emphasis is on comparative work that helps researchers judge which species and model systems are most informative and predictive for specific therapeutic questions, rather than relying on systems that may be convenient but misleading.
Browse more opportunities from the same category: Environment, Health
Next opportunity: PPHF16: Immunization –Improving Immunization Rates and Enhancing Disease Prevention through Partnerships with Providers and National Organizations that focus on Public Health – Financed Solely by 2016 Prevention and Public Health Funds
Previous opportunity: Assessing Human Placental Development and Function Using Existing Data (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 094
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 094) also looked into and applied for these:
| Funding Opportunity |
|---|
| Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01) Apply for PAR 16 128 Funding Number: PAR 16 128 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01) Apply for PAR 16 129 Funding Number: PAR 16 129 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $300,000 |
| Mechanism for Time-Sensitive Opportunity in Environmental Health Sciences (R21) Apply for RFA ES 16 005 Funding Number: RFA ES 16 005 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $200,000 |
| Collaborative Activities to Expedite Environmental Health Science Research, Translation, and Community Engagement Across EHS Core Centers (Admin Supp) Apply for PA 16 327 Funding Number: PA 16 327 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $100,000 |
| Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54) Apply for PAR 16 329 Funding Number: PAR 16 329 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $2,500,000 |
| Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01) Apply for PAR 16 331 Funding Number: PAR 16 331 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01) Apply for PAR 16 330 Funding Number: PAR 16 330 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $300,000 |
| NIH Big Data to Knowledge (BD2K) Enhancing Diversity in Biomedical Data Science (R25) Apply for RFA MD 16 002 Funding Number: RFA MD 16 002 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $300,000 |
| Collaborative Activities to Expedite Environmental Health Science Research, Translation, and Community Engagement Across EHS Core Centers (Admin Supp) Apply for PA 17 317 Funding Number: PA 17 317 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $100,000 |
| Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01) Apply for RFA CA 17 046 Funding Number: RFA CA 17 046 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $500,000 |
| Collaborative Activities to Expedite Environmental Health Science Research, Translation, and Community Engagement Across EHS Core Centers (Admin Supp - Clinical Trial Not Allowed) Apply for PA 18 770 Funding Number: PA 18 770 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $100,000 |
| Functional RNA Modifications Environment and Disease (FRAMED) (R21 Clinical Trial Not Allowed) Apply for RFA ES 19 002 Funding Number: RFA ES 19 002 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $150,000 |
| Functional RNA Modifications Environment and Disease (FRAMED) (R01 Clinical Trial Not Allowed) Apply for RFA ES 19 001 Funding Number: RFA ES 19 001 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $250,000 |
| NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE) (R25 Clinical Trial Not Allowed) Apply for RFA ES 20 015 Funding Number: RFA ES 20 015 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $200,000 |
| Alumni Engagement Innovation Fund 2022 Apply for PAS JOR FY22 003 Funding Number: PAS JOR FY22 003 Agency: Department of State, U.S. Mission to Jordan Category: Environment, Health Funding Amount: $40,000 |
| SBIR E-learning for HAZMAT and Emergency Response (R43/R44) Apply for RFA ES 16 006 Funding Number: RFA ES 16 006 Agency: National Institutes of Health Category: Environment, Health Funding Amount: Case Dependent |
| The Preconception Exposure Window and Health of the Offspring (R01) Apply for RFA ES 16 007 Funding Number: RFA ES 16 007 Agency: National Institutes of Health Category: Environment, Health Funding Amount: $300,000 |
| Transition to Independent Environmental Health Research (TIEHR) Career Transition Award (K01) Apply for PAR 16 360 Funding Number: PAR 16 360 Agency: National Institutes of Health Category: Environment, Health Funding Amount: Case Dependent |
| Revolutionizing Innovative, Visionary Environmental health Research (RIVER) (R35) Apply for RFA ES 16 008 Funding Number: RFA ES 16 008 Agency: National Institutes of Health Category: Environment, Health Funding Amount: $750,000 |
| Environmental Health Cohorts Maintenance and Infrastructure (R24) Apply for RFA ES 16 004 Funding Number: RFA ES 16 004 Agency: National Institutes of Health Category: Environment, Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 094", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.